课题基金 / 基金详情

UC DAVIS CLINICAL AND TRANSLATIONAL SCIENCE CENTER

UC DAVIS CLINICAL AND TRANSLATIONAL SCIENCE CENTER
加州大学戴维斯分校临床和转化科学中心
批准号:
8173865
负责人:
LARS F BERGLUND
金额:
$181.32万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2011-06-30

项目摘要

项目成果

LARS F BERGLUND的其他基金

相似基金

相关文献

中文摘要
翻译
本分项目是CTSA供资的估计百分比,即 被用于广泛的研究领域(艾滋病研究、儿科研究或 临床试验)。列出的总成本仅是对CTSA金额的估计 用于这一研究领域的基础设施,而不是由 授予子项目或子项目工作人员的NCRR补助金。 加州大学戴维斯分校(UC Davis)提议建立一个临床和翻译科学中心(CISC),它将把我们的医学研究企业转变为一个高效的临床和翻译研究的“开放”学术之家,建立在三个关键资产上:1)我们作为一所土地赠与大学的长期承诺,为地理上分散和种族多样化的人提供服务 2)加州大学戴维斯分校的协作文化,它拥有美国最广泛和跨学科的生命科学环境;3)成熟的CSTC试点设施-加州大学戴维斯分校临床研究研究员服务计划(CRISP),该计划是临床和翻译研究、教师培训和职业发展的有形之家。CRISP是一个从根本上重要的CTSC试验场,在那里我们探索了许多感知到的CTSA障碍并测试了解决方案,通过CRISP,我们完成了规划 CTSC的阶段。在加州大学戴维斯分校CTSC的组织结构中,相当注意创建一个组织:1)对调查人员作出反应并熟悉;2)灵活;3)与大学领导层、参与的学术单位和社区建立良好的联系;4)专注于以下目标 减少障碍,促进将研究成果转化为医疗实践。主要特点是:以团队科学为重点的教育计划;加州大学戴维斯分校各学院和中心之间的广泛合作;引入了协作研究促进器和翻译等催化剂功能 博士后奖学金;通过远程技术传播;灵活使用资源进行以病人为导向的研究;以及强调信任和尊重的社区参与方案。CTSC由两名联合首席调查员Berglund博士领导,他们是医学博士,博士(P.I.)由9个CTSC项目的主任和联席主任团队支持的Joseph MD博士(联席P.I.),以及旨在将CTSC与机构领导层、教职员工、受训人员和社区牢牢固定在一起的全面委员会结构。加州大学戴维斯分校的CTSC将通过精心设计的协作计划来实施,并将通过持续的评估和纠正来指导这项活动。
英文摘要
This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. The University of California, Davis (UC Davis) is proposing to create a Clinical and Translational Science Center (CISC) which will transform our medical research enterprise into a highly jeffective "open" academic home for clinical and translational research by building on three key assets: 1) Our long-standing commitment as a land-grant university to serve the geographically disperse and ethnically diverse populations of inland and Northern California with a health care system enabled by one of the broadest and most extensive telecommunications programs in the world; 2) The collaborative culture of UC Davis, which has one of the most extensive and interdisciplinary life science environments in the country, and 3) An established CSTC pilot facility - the UC Davis Clinical Research Investigator Services Program (CRISP) that serves as the physical home for clinical and translational research and for faculty training and career development. CRISP is a fundamentally important CTSC testing ground, where many perceived CTSA barriers have been explored and solutions tested, and through CRISP, we have completed the planning phase for the CTSC. In the organizational structure of the UC Davis CTSC, considerable attention is paid to create an organization that is: 1) responsive and familiar to investigators; 2) flexible; 3) well linked to university leadership, to participating academic units, and to the community; and 4) focused on the goal of reducing barriers and facilitating the translation of research gains into medical practice. Key features are: Education program focused on "team science"; Extensive collaborations across UC Davis colleges and centers; Introduction of catalyst functions such as Collaborative Research Facilitators and translational postdoctoral fellowships; Dissemination through tele-technology; Flexible use of resources for patientoriented research; and a Community engagement program emphasizing trust and respect. The CTSC is under the leadership of two co-Principal Investigators, Drs. Berglund MD, PhD, (P.I.) and Joseph MD, PhD (co-P.I.), supported by a team of Directors and co-Directors overseeing each of the 9 CTSC programs, and a comprehensive committee structure, designed to firmly anchor the CTSC with institutional leadership, faculty, trainees and the community. The UC Davis CTSC will be implemented through a carefully designed, collaborative plan, and the activity will be guided through continuous evaluations and corrections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UC Davis Clinical and Translational Science Center
  • 批准号:
    9261031
  • 项目类别:
  • 资助金额:
    $425.38万
  • 财政年份:
    2016
  • 负责人:
    LARS F BERGLUND
  • 依托单位:
Frontiers of University Training to Unlock the Research Enterprise (FUTURE)
Frontiers of University Training to Unlock the Research Enterprise (FUTURE)
Frontiers of University Training to Unlock the Research Enterprise (FUTURE)
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data